Hepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024
Hepatitis B Virus (HBV) Therapeutics
Market to Expand at a modest Compound
Annual Growth Rate (CAGR) of 2.4% Up to
The global hepatitis B market, which is set to experience limited growth from $2.4 billion in 2014 to $3
billion by 2024, is being stymied by the persistence of low diagnosis and treatment rates, according to
research. Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure
of viral clearance following acute HBV infection. Despite the availability of effective prophylactic
vaccines, the disease remains a serious global health concern, with estimated over 350 million people
worldwide currently living with this condition.
This report provides analysis of the hepatitis B therapeutics space across the eight major markets of the
US, France, Germany, Italy, Spain, the UK, Japan, and China, with annualized market data from 2014 and
forecast to 2024. It discusses strategic competitor assessment, unmet needs, pipeline assessment, and
market outlook for the hepatitis B therapeutics market.
Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Hepatitis B Virus
(HBV) Therapeutics Research Report at- http://www.absolutereports.com/pharmapoint-hepatitisb-virus-hbv-therapeutics-global-drug-forecast-and-market-analysis-to-2024-10112599
Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide
analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths
and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues
such as high accumulated treatment cost and low compliance.
Ask for Discount on Hepatitis B Virus (HBV) Research Report at –
+1 408 520 9750
Overview of chronic HBV infection, including epidemiology, etiology, pathophysiology,
symptoms, diagnosis, and current treatment options.
Top line HBV therapeutics market revenue from 2014–2024. Annual cost of therapy (ACOT) and
major pipeline product sales in this forecast period are included.
Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment,
and market outlook for the HBV therapeutics market.
Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10112599
In addition, Hepatitis B Virus (HBV) Therapeutics Report anticipates that opportunities centered on the
development of antivirals with novel MOAs, which can improve the efficacy of existing drugs, will exist
for current and future players in the HBV therapeutic marketplace for the duration of the forecast
Major key players covered in this report are Gilead, Bristol-Myers Squibb, Roche, Merck, GSK, Novartis,
Arrowhead Research and Globe Immune.
About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business
world in strategizing and taking visionary decisions based on facts and figures derived from in depth
market research. We are one of the top report resellers in the market, dedicated towards bringing you
an ingenious concoction of data parameters.
Mr. Ameya Pingaley
+1-408 520 9750
Email – [email protected]
+1 408 520 9750